Omics Approaches to Understanding the Efficacy and Safety of Disease-modifying Treatments in Multiple Sclerosis

Overview

Journal Front Genet

Date 2023 Feb 16

PMID 36793897

Authors

Lorena Lorefice

Maristella Pitzalis

Federica Murgia

Giuseppe Fenu

Luigi Atzori

Eleonora Cocco

Affiliations

Soon will be listed here.

Abstract

From the perspective of precision medicine, the challenge for the future is to improve the accuracy of diagnosis, prognosis, and prediction of therapeutic responses through the identification of biomarkers. In this framework, the sciences (genomics, transcriptomics, proteomics, and metabolomics) and their combined use represent innovative approaches for the exploration of the complexity and heterogeneity of multiple sclerosis (MS). This review examines the evidence currently available on the application of omics sciences to MS, analyses the methods, their limitations, the samples used, and their characteristics, with a particular focus on biomarkers associated with the disease state, exposure to disease-modifying treatments (DMTs), and drug efficacies and safety profiles.

Citing Articles

From in vivo models to in vitro bioengineered neuromuscular junctions for the study of Charcot-Marie-Tooth disease.

Scherrer C, Loret C, Vedrenne N, Buckley C, Lia A, Kermene V J Tissue Eng. 2025; 16:20417314241310508.

PMID: 40078221 PMC: 11898049. DOI: 10.1177/20417314241310508.

Propionic Acid Impact on Multiple Sclerosis: Evidence and Challenges.

Lorefice L, Zoledziewska M Nutrients. 2024; 16(22).

PMID: 39599673 PMC: 11597849. DOI: 10.3390/nu16223887.

The role of inflammation in neurological disorders: a brief overview of multiple sclerosis, Alzheimer's, and Parkinson's disease'.

Cantero-Fortiz Y, Boada M Front Neurol. 2024; 15:1439125.

PMID: 39539666 PMC: 11558529. DOI: 10.3389/fneur.2024.1439125.

Multi-omics profiling reveals peripheral blood biomarkers of multiple sclerosis: implications for diagnosis and stratification.

Zhou Q, Xie Z, He L, Sun G, Meng H, Luo Z Front Pharmacol. 2024; 15:1458046.

PMID: 39257402 PMC: 11384994. DOI: 10.3389/fphar.2024.1458046.

A Radiomic "Warning Sign" of Progression on Brain MRI in Individuals with MS.

Kelly B, Mathur P, McGuinness G, Dillon H, Lee E, Yeom K AJNR Am J Neuroradiol. 2024; 45(2):236-243.

PMID: 38216299 PMC: 11285987. DOI: 10.3174/ajnr.A8104.

References

Gafson A, Kim K, Cencioni M, Van Hecke W, Nicholas R, Baranzini S . Mononuclear cell transcriptome changes associated with dimethyl fumarate in MS. Neurol Neuroimmunol Neuroinflamm. 2018; 5(4):e470. PMC: 6168332. DOI: 10.1212/NXI.0000000000000470. View

Nelson M, Tipney H, Painter J, Shen J, Nicoletti P, Shen Y . The support of human genetic evidence for approved drug indications. Nat Genet. 2015; 47(8):856-60. DOI: 10.1038/ng.3314. View

Reale M, Sanchez-Ramon S . Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis. Curr Med Chem. 2016; 24(2):176-192. DOI: 10.2174/0929867324666161123093606. View

Rajda C, Pukoli D, Bende Z, Majlath Z, Vecsei L . Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis. Int J Mol Sci. 2017; 18(2). PMC: 5343888. DOI: 10.3390/ijms18020353. View

Bos S, Page C, Andreassen B, Elboudwarej E, Gustavsen M, Briggs F . Genome-wide DNA methylation profiles indicate CD8+ T cell hypermethylation in multiple sclerosis. PLoS One. 2015; 10(3):e0117403. PMC: 4348521. DOI: 10.1371/journal.pone.0117403. View

Villoslada P, Baranzini S . Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis. J Neuroimmunol. 2012; 248(1-2):58-65. DOI: 10.1016/j.jneuroim.2012.01.001. View

Spicer R, Salek R, Steinbeck C . A decade after the metabolomics standards initiative it's time for a revision. Sci Data. 2018; 4:170138. PMC: 6038898. DOI: 10.1038/sdata.2017.138. View

Wallin M, Oh U, Nyalwidhe J, Semmes J, Kislinger T, Coffman P . Serum proteomic analysis of a pre-symptomatic multiple sclerosis cohort. Eur J Neurol. 2014; 22(3):591-9. DOI: 10.1111/ene.12534. View

Kasakin M, Rogachev A, Predtechenskaya E, Zaigraev V, Koval V, Pokrovsky A . Targeted metabolomics approach for identification of relapsing-remitting multiple sclerosis markers and evaluation of diagnostic models. Medchemcomm. 2019; 10(10):1803-1809. PMC: 6849630. DOI: 10.1039/c9md00253g. View

10.

Haider L, Fischer M, Frischer J, Bauer J, Hoftberger R, Botond G . Oxidative damage in multiple sclerosis lesions. Brain. 2011; 134(Pt 7):1914-24. PMC: 3122372. DOI: 10.1093/brain/awr128. View

11.

Faissner S, Gold R . Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments. CNS Drugs. 2022; 36(8):803-817. PMC: 9307218. DOI: 10.1007/s40263-022-00939-9. View

12.

Nogueras L, Gonzalo H, Jove M, Sol J, Gil-Sanchez A, Hervas J . Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis. Sci Rep. 2019; 9(1):11313. PMC: 6683197. DOI: 10.1038/s41598-019-47906-x. View

13.

Del Boccio P, Pieragostino D, Di Ioia M, Petrucci F, Lugaresi A, De Luca G . Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis. J Proteomics. 2011; 74(12):2826-36. DOI: 10.1016/j.jprot.2011.06.023. View

14.

Ferreira H, Neves B, Guerra I, Moreira A, Melo T, Paiva A . An overview of lipidomic analysis in different human matrices of multiple sclerosis. Mult Scler Relat Disord. 2020; 44:102189. DOI: 10.1016/j.msard.2020.102189. View

15.

Olsson T, Barcellos L, Alfredsson L . Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2016; 13(1):25-36. DOI: 10.1038/nrneurol.2016.187. View

16.

Jacobs B, Taylor T, Awad A, Baker D, Giovanonni G, Noyce A . Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis. Brain Commun. 2020; 2(2):fcaa119. PMC: 7519728. DOI: 10.1093/braincomms/fcaa119. View

17.

Bhargava P, Fitzgerald K, Calabresi P, Mowry E . Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight. 2017; 2(19). PMC: 5841876. DOI: 10.1172/jci.insight.95302. View

18.

Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G . Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. Pharmacogenomics J. 2016; 17(4):312-318. DOI: 10.1038/tpj.2016.20. View

19.

Andlauer T, Buck D, Antony G, Bayas A, Bechmann L, Berthele A . Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Sci Adv. 2016; 2(6):e1501678. PMC: 4928990. DOI: 10.1126/sciadv.1501678. View

20.

Pousinis P, Ramos I, Woodroofe M, Cole L . Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis. Metabolites. 2020; 10(9). PMC: 7569864. DOI: 10.3390/metabo10090366. View